Shapuaisi obtains drug registration certificate for tafluprost eye drops
March 19, 2025
Source: drugdu
36
On March 17, Shapuaisi (603168) issued an announcement that the company recently obtained the "Drug Registration Certificate" for tafluprost eye drops approved and issued by the State Drug Administration.
The drug is an ophthalmic preparation with a specification of 0.0015% (0.3ml: 4.5μg) and is registered as Class 4 chemical drugs. The company's cumulative R&D investment in the drug is approximately RMB 6.46 million.
Obtaining a drug registration certificate will help enrich the company's product categories and optimize product layout. However, the future production and sales of the drug will still face many uncertain factors such as changes in pharmaceutical industry policies, bidding and procurement, and market environment, so there is uncertainty about the impact on the company's performance.
https://finance.eastmoney.com/a/202503173347698684.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- JSKN003 Receives Breakthrough Therapy Designation in China March 19, 2025
- Huiyu Pharmaceuticals Obtains Drug Registration Certificate for Melphalan Hydrochloride March 19, 2025
- Two drugs were included in the “Rare Disease Drug Development “Care Plan” March 19, 2025
- First proof, first installment! Two medical devices approved for market launch March 18, 2025
- “Gastrointestinal Endoscopic Surgical Instrument Control Equipment” is approved for market launch March 18, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
